Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of vicadrostat with empagliflozin using simultaneous versus staggered initiation in chronic kidney disease
CTR20253076Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vicadrostat, empagliflozin in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Sep 2025; status: active.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20253076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253076.